<DOC>
	<DOCNO>NCT02324569</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety SYR-472 administer dose 100 mg weekly add-on insulin therapy ( SYR-472 100 mg combination/SYR-472 100 mg combination group ) use insulin preparation alone/ SYR-472 100 mg combination group control patient type 2 diabetes mellitus inadequate glycemic control despite treatment insulin preparation addition diet and/or exercise therapy ; evaluate long-term efficacy safety SYR-472 administer dose 100 mg weekly add-on insulin therapy patient type 2 diabetes mellitus inadequate glycemic control despite treatment insulin preparation addition diet and/or exercise therapy .</brief_summary>
	<brief_title>A Phase 3 , Randomized , Double-blind , Parallel-group , Comparative Study Phase 3 , Open-label , Long-term Study SYR-472 ( 100 mg ) Combination With Insulin Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This phase 3 , multicenter , randomize , double-blind , parallel-group , comparative study use insulin preparation alone/SYR-472 100 mg combination group control ( Treatment Period I ) phase 3 , multicenter , open-label , long-term study ( Treatment Period II ) evaluate efficacy safety SYR-472 administer dose 100 mg add-on insulin therapy ( SYR-472 100 mg combination/SYR-472 100 mg combination group ) patient type 2 diabetes mellitus inadequate glycemic control despite treatment insulin preparation addition diet and/or exercise therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Participant eligibility determine accord follow criterion : 1 . The participant diagnosis type 2 diabetes mellitus . 2 . The participant fasting Cpeptide level 0.6 ng/mL high start screen period ( Week 6 ) Week 2 screening period . 3 . The participant HbA1c value 7.5 % high less 10.0 % Week 2 screening period . 4 . The participant HbA1c value difference start screen period ( Week 6 ) Week 2 screening period within 10.0 % * ( * round one decimal place ) HbA1c value start screen period ( Week 6 ) . 5 . The participant fix diet and/or exercise therapy ( ) least 6 week prior start screen period ( Week 6 ) . 6 . The participant treat insulin preparation alone ( ≥8 units/day ≤40 units/day ) ** least 6 week prior start screen period ( Week 6 ) fix dose regimen insulin preparation . The participant one follow insulin monotherapies : mixed ( rapidacting shortacting insulin contain 30 % volume ) , intermediateacting , longacting soluble insulin preparation 7 . The participant deem appropriate treatment combination insulin another antidiabetic drug start screen period ( Week 6 ) investigator subinvestigator . 8 . The participant control stable blood pressure need change dose antihypertensive drug ( include discontinuation suspension ) additional antihypertensive drug study period assess investigator subinvestigator . 9 . The participant male female age 20 year old time inform consent . 10 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent one month end study . 11 . In opinion investigator subinvestigator , participant capable understand comply protocol requirement . 12 . The participant sign date write , informed consent form prior initiation study procedure . Any participant meet follow criterion qualify entry study : 1 . The participant clinical manifestation hepatic impairment [ e.g. , AST ALT ≥2.5 time upper limit normal total bilirubin ≥2.0 mg/dL start screen period ( Week 6 ) Week 2 screening period ] . 2 . The participant moderate severe renal impairment endstage renal failure [ e.g. , creatinine clearance ( Ccr ) &lt; 50 mL/min start screen period ( Week 6 ) Week 2 screening period ] . 3 . The participant serious cardiac disease , cerebrovascular disorder , serious pancreatic hematological disease ( e.g. , participant require inpatient treatment hospitalize treatment within 24 week prior start screen period ) . 4 . The participant , judgment investigator subinvestigator , clinically significant abnormal hematological parameter hemoglobin , hematocrit , erythrocytes start screen period ( Week 6 ) Week 2 screening period . 5 . The participant systolic blood pressure 180 mmHg high diastolic blood pressure 110 mmHg high screening period . 6 . The participant least two antidiabetic therapy one insulin preparation one day 6 week prior start screen period ( Week 6 ) ( 43 day prior start screen period ) . 7 . The participant alter dose regimen insulin preparation within 6 week prior start screen period screen period . 8 . The participant experience hypoglycemia ( participant blood glucose level ≤70 mg/dL hypoglycemic symptom ) within 6 week prior start screen period screen period ( least twice per week ) . 9 . The participant fasting blood glucose level 240 mg/dL high start screen period ( Week 6 ) Week 2 screening period . 10 . The participant malignancy . 11 . The participant history hypersensitivity allergy dipeptidyl peptidase 4 ( DPP4 ) inhibitor insulin preparation . 12 . The participant history gastrectomy small intestinal resection . 13 . The participant habitual drinker consume daily average 100 mL alcohol . 14 . The participant history drug abuse ( define use illegal drug ) alcohol dependence . 15 . The participant require take excluded medication study period . 16 . The participant receive SYR472 previous clinical study . 17 . The participant deem condition contraindicate treatment specify package insert insulin preparation investigator subinvestigator . 18 . The participant receive investigational product ( include study drug postmarketing clinical study ) within 12 week prior start screen period . 19 . The participant participate clinical study time inform consent . 20 . If female , participant pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 21 . The participant immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 22 . The participant hospitalized screening period deem require hospitalization study period investigator subinvestigator , unless hospitalization shortterm evaluation include complete health checkup . 23 . The participant deem ineligible study reason investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>